Survival after autologous hematopoietic stem cell transplantation for patients with inflammatory breast carcinoma

Cancer

Volumn 85, Issue 1, 1999, Pages 93-99

  Arun, Banu ^a,c   Slack, Rebecca ^a   Gehan, Edmund ^a   Spitzer, Thomas ^b   Meehan, Kenneth R ^a,d  

^a GEORGETOWN UNIVERSITY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Dose intensity; Inflammatory breast carcinoma; Survival; Transplantation

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; AMPHOTERICIN B; CARBOPLATIN; CIPROFLOXACIN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 2; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CELL TRANSPLANTATION; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOTHERAPY; MAMMOGRAPHY; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RECURRENCE RISK; STATISTICAL ANALYSIS; TREATMENT PLANNING;

ADENOCARCINOMA; ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-2; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 0032893248     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990101)85:1<93::AID-CNCR13>3.0.CO;2-C     Document Type: Article

References (27)

1. Hortobagyi GH, Singletary SE, McNesse MD. Treatment of locally advanced and inflammatory breast cancer. In: Harris JR, Lippman ME, Morrow M, Hellman S, editors. Diseases of the breast. Philadelphia: Lippencott-Raven, 1996:585-98.
2. Early Breast Cancer Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992;339:1-15, 71-85.
3. Fisher B, Wickerham DL, Redmond C. Recent developments in the use of systemic adjuvant therapy for the treatment of breast cancer. Semin Oncol 1992;19(3):263-77.
4. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984;2(11):1281-8.
5. Hryniuk W, Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 1986;4(8):1162-70.
6. Gianni AM, Bregni M, Siena S, Orazi A, Stern AC, Gandola L, et al. Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma. J Clin Oncol 1990;8:768-78.
7. Perkins JB, Effenbein GJ, Fields KK. Analysis of dose-response relationships in the setting of high-dose ifosfamide, carboplatin, and etoposide and autologous hematopoietic stem cell transplantation: implications for the treatment of patients with advanced breast cancer. Semin Oncol 1996; 23(3 Suppl 6):42-6.
8. Holland KH, Dix PD, Getter RB, Devine SM, Heffner LT, Connaghan DG, et al. Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care. J Clin Oncol 1996;14(4):1156-64.
9. Somlo G, Doroshow JH, Forman SJ, Leong LA, Margolin KA, Morgan RJ Jr., et al. High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer. Cancer 1994;73(1):125-34.
10. Nieto Y, Cagnoni PJ, Beraman SI, Shpall EJ, Ross M, Jones RB. High-dose chemotherapy (HDC) with cisplatin (cDDP), cyclophosphamide (CPA) and BCNU (CCB), followed by autologous hematopoietic progenitor cell support (AHPCS) for inflammatory breast cancer (IBC) [abstract]. Proc Am Soc Clin Oncol 1997;16:436.
11. Rosti G, Vertogen B, Ferrante P, Turazza M, Lelli G, Dabbatini R, et al. High-dose mitoxantrone, thiotepa and cyclophosphamide with peripheral blood progenitor cells (PBPC) support for inflammatory breast carcinoma; an Italian study [abstract]. Proc Am Soc Clin Oncol 1997;16:440.
12. Adkins DR, Brown RA, Beck E, Khoury H, Freytes C, Bachier, et al. Outcomes of high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) in stage IIIB inflammatory breast cancer (IBC) [abstract]. Proc Am Soc Clin Oncol 1997;16:363.
13. Ayash L, Elias A, Ibrahim J, Schwartz G, Wheeler C, Reich E, et al. High-dose multimodality therapy with autologous stem cell support for stage IIIB breast cancer: the DFCI/BIH experience [abstract]. Proc Am Soc Clin Oncol 1997;16:318.
14. Gianni AM, Siena A, Bregni M, Di Nicola M, Orefice S, Luini A, et al. Growth factor supported high-dose sequential (HDS) adjuvant chemotherapy in breast cancer with ≥ 10 positive nodes [abstract]. Proc Am Soc Clin Oncol 1992;11: 68.
15. Mulder NH, Sleijfer DTH, DeVries EGR, Mulder PVD, Graaf WTA, Ploeg VD, et al. Intensive chemotherapy with autologous bone marrow reinfusion in patients with breast cancer and more than 5 involved lymph nodes [abstract]. Proc Am Soc Clin Oncol 1993;12:104.
16. Peters WP, Ross M, Vredenburgh JJ, Meisenberg B, Marks LB, Winer E, et al. High dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993;11:1132-43.
17. Antman KH, Rowlings PA, Vaughan WP, Pelz CJ, Fay JW, Fields KK, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer. J Clin Oncol 1997;15(5):1870-9.
18. Spitzer TR, Cirenza E, McAfee S, Foelber R, Zarzin J, Cahill R, et al. Phase I-II trial of high dose cyclophosphamide, carboplatin and autologous bone marrow or peripheral blood stem cell rescue. Bone Marrow Transplant 1995;15(4):537-42.
19. Meehan KR, Verma UN, Rajagopal C, Cahill R, Frankel S, Lippman M, et al. Interleukin-2 activated hematopoietic stem cell transplantation for breast cancer: clinical and biological correlates. Bone Marrow Transplant 1997;20(8):643-51.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
21. Gehan EA. A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrica 1965;52:203-23.
22. Cox DR. Regression models and life tables. J R Stat Soc 1972;34:187-220.
23. Piccart MJ, de Valeriola D, Paridaens R, Balikdjian D, Mattheiem WH, Loriaux C, et al. Six-year results of a multimodality treatment strategy for locally advanced breast cancer. Cancer 1988;62(12):2501-6.
24. Rouesse J, Friedman S, Sarrazin D, Mouriesse H, Le Chevalier T, Arriagada R, et al. Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave-Roussy. J Clin Oncol 1986; 4(12):1765-71.
25. Gardin G, Rosso R, Campora E, Repetto L, Naso C, Canavese G, et al. Locally advanced non-metastatic breast cancer: analysis of prognostic factors in 125 patients homogeneously treated with a combined modality approach. Eur J Cancer 1995;31A(9):1428-33.
26. Somlo G, Doroshow JH, Forman SJ, Odom-Maryon P, Lee J, Chow W, et al. High dose chemotherapy and stem cell rescue in the treatment of high risk breast cancer: prognostic indicators off progression-free and overall survival. J Clin Oncol 1997;15(8):2882-93.
27. Levine PH, Steinhorn SC, Ries LG, Aaron LJ. Inflammatory breast cancer: the experience of the Surveillance, Epidemology and End Results (SEER) program. J Natl Cancer Inst 1985;74-291-7.